Melissa Hollo: Intravenous Iron Shows Better Results Than Oral Iron in Pregnancy
Melissa Hollo, Director of Project Management at hc1 and Licensed Independent Clinical Social Worker, shared Robert Brown’s post on LinkedIn, adding:
”A well-done study in Obstetrics and Gynecology reinforcing what many of us are seeing in practice:
Intravenous ferumoxytol isn’t just an alternative to oral iron in pregnancy, it’s more effective.
This randomized trial shows:
- Significantly greater increases in hemoglobin with IV ferumoxytol vs oral ferrous sulfate
- Meaningful improvements in ferritin and iron indices
- Better correction of anemia by the time of delivery
For a condition as common, and consequential, as iron deficiency anemia in pregnancy, this matters.
We cannot continue to rely on oral iron alone when:
- Absorption is variable
- Tolerability limits adherence
- Time to correction is often too slow for the peripartum window
This is exactly why earlier identification and more effective treatment pathways are critical.
The takeaway is clear:
If we are serious about improving maternal outcomes, IV iron should be considered sooner, not later.
Learn how we’re supporting earlier maternal risk detection.”
Robert Brown, Academic Obstetrician, shared a post on LinkedIn about a recent article by Irogue I Igbinosa, published in Obstetrics and Gynecology։
”IV iron versus oral iron pregnancy anemia.”
Title: Intravenous Ferumoxytol Compared With Oral Ferrous Sulfate for Iron Deficiency Anemia in Pregnancy
A Randomized Controlled Trial
Authors: Irogue I Igbinosa, Stephanie A Leonard, Ijeoma Iwekaogwu, Elizabeth B Sherwin, Caroline Berube, Deirdre J Lyell
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 11, 2026, 16:46Moaz Abouelmagd: Key Findings from a Large Network Meta-Analysis of IV Thrombolytics in Acute Ischemic Stroke
-
Jun 11, 2026, 16:37Wolfgang Miesbach: From Failed Intravitreal Trials to Real Benefit – Subretinal AAV8 Gene Therapy in Pediatric X-Linked Retinoschisis
-
Jun 11, 2026, 16:34Joao Mariano Pego: Advancing Coagulation Diagnostics Through Standardized Thrombin Generation
-
Jun 11, 2026, 16:33Ifeanyichukwu Ifechidere: Nobody Talks About Thrombosis in Sickle Cell Disease
-
Jun 11, 2026, 16:31Karim Mahawish: Ischaemic Stroke Despite Anticoagulation in Atrial Fibrillation
-
Jun 11, 2026, 16:29Salim Virani: The 2026 ACC/AHA Multisociety Dyslipidemia Guideline Promotes Early Prevention
-
Jun 11, 2026, 16:25Toyosi Onwuemene: What Clinicians Reveal About Bleeding and Clotting Care
-
Jun 11, 2026, 16:20Tejas Ahire: Rh Incompatibility – A Small Blood Group Difference with Big Clinical Impact
-
Jun 11, 2026, 16:19Jack Shuang Hou: Bayer Advances Asundexian as EMA Reviews New Option for Preventing Recurrent Ischemic Stroke